Gunawardena Thilina
Department of vascular and transplant surgery, National Hospital of Sri Lanka, Colombo, Sri Lanka.
Hematol Rep. 2021 Nov 26;13(4):9239. doi: 10.4081/hr.2021.9239.
Thrombin inhibitors and direct factor Xa inhibitors represent a major breakthrough in the field of anticoagulation pharmacotherapy. These novel agents have replaced warfarin as the oral anticoagulant of choice in certain indications, as they possess equal or superior efficacy and better safety profiles. They have a quick onset of action, predictable pharmacokinetic properties and minimal drug and food interactions. So they do not require frequent blood monitoring and dose adjustments as with warfarin. Considering all the advantages, there seems to be a rapid increase in the number of patients who are started on these novel anticoagulants. In this review, we highlight the pharmacology of these direct oral anticoagulants and the evidence-based indications for their use. We aim to provide a clinical overview for the non-specialist who may be called upon to manage a patient who is currently on one of these novel anticoagulants.
凝血酶抑制剂和直接Xa因子抑制剂代表了抗凝药物治疗领域的一项重大突破。这些新型药物已在某些适应症中取代华法林成为口服抗凝药的首选,因为它们具有同等或更高的疗效以及更好的安全性。它们起效迅速,药代动力学特性可预测,药物与食物相互作用极少。因此,它们不像华法林那样需要频繁的血液监测和剂量调整。考虑到所有这些优势,开始使用这些新型抗凝药的患者数量似乎在迅速增加。在本综述中,我们重点介绍这些直接口服抗凝药的药理学及其基于证据的使用适应症。我们旨在为可能需要管理正在使用这些新型抗凝药之一的患者的非专科医生提供临床概述。